Antiangiogenic gene therapy

Jarosław Szary; Stanisław Szala; Urszula Wilczyńska

Abstract

4/1999 vol. 3

Antiangiogenic gene therapy

Jarosław Szary

,

Stanisław Szala

,

Urszula Wilczyńska

Współcz Onkol (1999) 4, 139-142

Online publish date: 2003/08/05

View full text

AMA

Szary J, Szala S, Wilczyńska U. Antiangiogenic gene therapy. Contemporary Oncology/Współczesna Onkologia. 1999;3(4):139-142.

APA

Szary, J., Szala, S., & Wilczyńska, U. (1999). Antiangiogenic gene therapy. Contemporary Oncology/Współczesna Onkologia, 3(4), 139-142.

Chicago

Szary, Jarosław, Stanisław Szala, and Urszula Wilczyńska. 1999. "Antiangiogenic gene therapy". Contemporary Oncology/Współczesna Onkologia 3 (4): 139-142.

Harvard

Szary, J., Szala, S., and Wilczyńska, U. (1999). Antiangiogenic gene therapy. Contemporary Oncology/Współczesna Onkologia, 3(4), pp.139-142.

MLA

Szary, Jarosław et al. "Antiangiogenic gene therapy." Contemporary Oncology/Współczesna Onkologia, vol. 3, no. 4, 1999, pp. 139-142.

Vancouver

Szary J, Szala S, Wilczyńska U. Antiangiogenic gene therapy. Contemporary Oncology/Współczesna Onkologia. 1999;3(4):139-142.

Several data show that transfer of sequences encoding angiostatin, endostatin or trucated receptors for VEGF can be used to inhibit tumor growth and metastasis.

Keywords

angiogenesis, cancer gene therapy, VEGF receptors, angiostatin, endostatin

Abstract

Antiangiogenic gene therapy

Keywords

Share

Coverage in

Indexed in

Integrated with

Editorial Policies